Theriva Biologics, Inc.
COMPANY
10-Q
FORM
2025-05-14
FILING DATE
2025-03-31
Q1 PERIOD END
553
FACTS
SIC 2834
CIK 0000894158
Taxonomy US GAAP 2024  
SIC 2834
CIK 0000894158
Taxonomy US GAAP 2024  
Standard Concepts
258
Extended Concepts
73
22%
Extended Concepts
Errors
0
What are errors?
What are errors?
Indicate problems with an XBRL formatted filing that are sufficient grounds for SEC rejection of the XBRL portion of the filing.
Data Quality Errors
0
What are data quality errors?
What are data quality errors?
Indicate areas that may not meet the standards set by the Data Quality Committee (DQC), and may reveal areas where the XBRL can be improved.
Possible Issues
2
WARNING
8 fact(s) appearing in ix:hidden were eligible for transformation: tovx:LeaseRentAbatementPeriod1, tovx:LesseeOperatingLeaseShortTermAgreementTerm, tovx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantExpirationsInPeriod, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1, us-gaap:WarrantsAndRightsOutstandingTerm
WARNING
2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies
What are possible issues?
What are possible issues?
Indicate areas of interest as to the quality of an XBRL formatted filing, and in some cases reveal opportunities for improvement of the XBRL filing.
SEC: Filing | Interactive Data